Skip to main content
Premium Trial:

Request an Annual Quote

'Improved Pharma Demand' Helps Waters' Q4 Sales Surge 17 Percent

NEW YORK (GenomeWeb News) — Waters today said fourth-quarter 2006 revenues increased 17 percent on strong pharma demand as R&D spending rose 17 percent and profit widened 6 percent.
 
Total receipts for the three months ended Dec. 31, 2006, increased to $387 million from $332 million year over year. 
 
CEO Douglas Berthiaume said most of the revenue surge came from “improved pharmaceutical demand, continued growth in our overseas markets, and strong sales growth by our TA instruments division.”
 
Foreign currency translation was responsible for 3 percent of the increased revenue, the company said.
 
R&D spending increased to $19.5 million from $16.7 million year over year.
 
Waters said profits for the quarter grew to $78.9 million from $75.6 million in the year-ago period.
 
Waters said it had around $514.2 million in cash and equivalents as of Dec. 31, 2006.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.